Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
855566
Reference Type
Journal Article
Subtype
Review
Title
Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review
Author(s)
Carella, AM; Antonucci, G; Conte, M; Di Pumpo, M; Giancola, A; Antonucci, E
Year
2010
Is Peer Reviewed?
Yes
Journal
Current Diabetes Reviews
ISSN:
1573-3998
Volume
6
Issue
4
Page Numbers
215-221
Language
English
PMID
20459394
DOI
10.2174/157339910791658844
URL
http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-3998&volume=6&issue=4&spage=215
Exit
Abstract
Metabolic syndrome, a "cluster" of metabolic disorders including hypertension, increases the cardiovascular risk, and insulin resistance plays a key role in its pathogenesis. In this syndrome antihypertensive treatment with beta-blockers is underused because of their adverse metabolic effects. The aim was to review the evidences supporting the reasons for underusing beta-blockers in hypertensive patients with metabolic syndrome. A review of Literature has been carried out via PubMed from 1998 to 2008: most of beta-blockers have adverse effects on insulin sensitivity, carbohydrate and lipid metabolism, and are not recommended in metabolic syndrome. However, some recent large studies have shown a better metabolic profile with newer third generation vasodilating beta-blockers, such as Carvedilol and Nebivolol. Vasodilating action of Carvedilol and Nebivolol, due respectively to alpha1-blocking effect and release of nitric oxide, explains the lack of adverse metabolic effects of these beta-blockers that could also be used in hypertensive patients with metabolic syndrome.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity